Search

Your search keyword '"Spiazzi, L."' showing total 25 results
Start Over Author "Spiazzi, L." Database OpenAIRE
25 results on '"Spiazzi, L."'

4. Intensity Modulated Proton Therapy (IMPT) vs Intensity Modulated Radiation Therapy (IMRT)in malignant pleural mesothelioma (MPM): a dosimetric comparison

Author

Lorentini, S, Hamer, P, Amichetti, M, Spiazzi, L, Tonoli, S, Magrini, S, and Schwarz, M

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Background: Recently the trimodality approach (neoadjuvant chemotherapy, extrapleural pneumonectomy and hemithoracic irradiation) is increasingly used for patients (pts) affected by MPM. With IMRT an increase in therapeutic dose to the pleural cavity and a reduction of doses to organs at risk (OAR) [for full text, please go to the a.m. URL], PTCOG 48; Meeting of the Particle Therapy Co-Operative Group

Published
2009
Full Text
View/download PDF

21. Reduced Excretion of Vasodilator Prostaglandins in Preeclampsia

Author

Lechi A, M. Corsato, M. Degan, Minuz P, Probitzer P, Covi G, Francesca Paluani, Lechi C, and Spiazzi L

Subjects
medicine.medical_specialty, Prostaglandin, Alpha (ethology), Vasodilation, Kallikrein, Urine, medicine.disease, Preeclampsia, Excretion, chemistry.chemical_compound, Urinary excretion, Endocrinology, chemistry, Internal medicine, cardiovascular system, medicine, lipids (amino acids, peptides, and proteins), circulatory and respiratory physiology
Abstract

The role of prostaglandin (PG) system in preeclampsia (pre-E) was investigated. Urinary excretion of PGE2,6-keto PGF1 alpha,2,3 dinor 6-keto PGF1 alpha, TxB2 and 2,3-dinor-TxB2 and kallikrein were determined in 10 normotensive pregnant women and 14 with pre-E. 6-keto PGF1 alpha and 2,3-dinor 6-keto PGF1 alpha (the main renal and extrarenal metabolites of vasodilator PGI2) and PGE2 excretion was lower in pre-E. TxB2 metabolites in urine were similar in the two groups of women. Our data are consistent with the hypothesis of an imbalance between vasodilator and vasoconstrictor PGs in pre-E.

Published
1987
Full Text
View/download PDF

24. The potential role of SPECT/CT in the clinical management of COVID-19 lung cancer patients undergoing radiotherapy

Author

Cristian Toraci, Jessica Imbrescia, Andrea Emanuele Guerini, Alessandro Magli, Salvatore Cappabianca, Luigi Spiazzi, Silvia Lucchini, Giulia Volpi, Alfonso Reginelli, Valerio Nardone, Paolo Borghetti, Stefano Maria Magrini, Borghetti, P., Toraci, C., Imbrescia, J., Volpi, G., Lucchini, S., Guerini, A. E., Magli, A., Spiazzi, L., Reginelli, A., Cappabianca, S., Magrini, S. M., and Nardone, V.

Subjects
Oncology, medicine.medical_specialty, 2019-20 coronavirus outbreak, Single Photon Emission Computed Tomography Computed Tomography, Lung Neoplasms, Coronavirus disease 2019 (COVID-19), SARS-CoV-2, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), medicine.medical_treatment, MEDLINE, COVID-19, General Medicine, medicine.disease, Radiation therapy, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Lung cancer, business, Human
Published
2021
Full Text
View/download PDF

25. How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Radiotherapy and Clinical Oncology (AIRO)

Author

Stefania Gottardo, Diana Greco, Simona Borghesi, Beatrice Detti, Gianluca Ingrosso, Paolo Antognoni, Umberto Ricardi, Alessandro Magli, Stefano Maria Magrini, Ercole Mazzeo, Luigi Spiazzi, Andrea Emanuele Guerini, Luca Frassinelli, Sara Nanni, Sara Bartoncini, Frank Lohr, Alessio Bruni, Rolando Maria D'Angelillo, Giulio Francolini, Stefano Arcangeli, Alessia Guarneri, Luca Triggiani, Mazzeo, E, Triggiani, L, Frassinelli, L, Guarneri, A, Bartoncini, S, Antognoni, P, Gottardo, S, Greco, D, Borghesi, S, Nanni, S, Bruni, A, Ingrosso, G, D'Angelillo, R, Detti, B, Francolini, G, Magli, A, Guerini, A, Arcangeli, S, Spiazzi, L, Ricardi, U, Lohr, F, and Magrini, S

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, genetic structures, medicine.medical_treatment, behavioral disciplines and activities, Article, Settore MED/06, Pattern Of Practice, Late toxicity, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Settore MED/36, Internal medicine, medicine, External beam radiotherapy, RC254-282, radiotherapy, Image-guided radiation therapy, Clinical Oncology, Radiotherapy, urogenital system, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, prostate cancer, Acute toxicity, body regions, Radiation therapy, 030104 developmental biology, 030220 oncology & carcinogenesis, Toxicity, business, psychological phenomena and processes
Abstract

Background and purpose: Two previous “Patterns Of Practice” surveys (POP I and POP II), including more than 4000 patients affected by prostate cancer treated with radical external beam radiotherapy (EBRT) between 1980 and 2003, established a “benchmark” Italian data source for prostate cancer radiotherapy. This report (POP III) updates the previous studies. Methods: Data on clinical management and outcome of 2525 prostate cancer patients treated by EBRT from 2004 to 2011 were collected and compared with POP II and, when feasible, also with POP I. This report provides data on clinical presentation, diagnostic workup, radiation therapy management, and toxicity as collected within the framework of POP III. Results: More than 50% of POP III patients were classified as low or intermediate risk using D’Amico risk categories as in POP II, 46% were classified as ISUP grade group 1. CT scan, bone scan, and endorectal ultrasound were less frequently prescribed. Dose-escalated radiotherapy (RT), intensity modulated radiotherapy (IMRT), image guided radiotherapy (IGRT), and hypofractionated RT were more frequently offered during the study period. Treatment was commonly well tolerated. Acute toxicity improved compared to the previous series, late toxicity was influenced by prescribed dose and treatment technique. Five-year overall survival, biochemical relapse free survival (BRFS), and disease specific survival were similar to those of the previous series (POP II). BRFS was better in intermediate- and high-risk patients treated with ≥ 76 Gy. Conclusions: This report highlights the improvements in radiotherapy planning and dose delivery among Italian Centers in the 2004–2011 period. Dose-escalated treatments resulted in better biochemical control with a reduction in acute toxicity and higher but acceptable late toxicity, as not yet comprehensively associated with IMRT/IGRT. CTV-PTV margins &gt, 8 mm were associated with increased toxicity, again suggesting that IGRT—allowing for tighter margins—would reduce toxicity for dose escalated RT. These conclusions confirm the data obtained from randomized controlled studies.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results